AVTX-002 not checked

Avalo Therapeutics, Inc. · CERC-002 · AEVI-002 and MDGN-002

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.”In the company’s words, NCT04412057 on ClinicalTrials.gov
Tested for
COVID-19 Pneumonia, Acute Lung Injury, ARDS, Non-Eosinophilic Asthma, Crohn Disease, Ulcerative Colitis
Main trialPhase 2
“The study is a prospective, randomized, placebo-controlled, double-blind phase 2 clinical study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator, a receptor expressed by T lymphocytes), for the treatment of patients with 2019 novel coronavirus disease (COVID-19) pneumonia who have mild to moderate Acute Respiratory Distress Syndrome (ARDS). LIGHT is a cytokine in the tumor necrosis factor super family (TNFSF14) which drives inflammation and induces…”In the company’s words, NCT04412057 on ClinicalTrials.gov
Other names
CERC-002 · AEVI-002 and MDGN-002 · MDGN-002 · AEVI-002

Other drugs for COVID-19 Pneumonia

All 43 drugs for COVID-19 Pneumonia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Completed 14 Dec 2020 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Phase 2Completed 11 May 2023 A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Phase 1Terminated 14 Sep 2021 Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AVTX-002

Following is part of Solo: you see every change to AVTX-002 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in